Skip to content

Jose Antonio Sacristan

  • MD, PhD, MBA
  • Senior Medical Director
  • Eli Lilly and Company
  • 23h-indexImpact measure calculated using publication and citation counts. Updated daily.
  • 2190CitationsNumber of citations received by Jose Antonio's publications. Updated daily.

Research interests

Outcomes researchReal world evidencePragmatic studiesCost-effectivenessPatients and clinical researchPatient-centered medicine

Co-authors (273)

  • Ilya Klabukov

Publications (5)

  • Pragmatic trials revisited: Applicability is about individualization

    • Sacristán J
    • Dilla T
    N/AReaders
    0Citations
    Get full text
  • Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain

    • Agúndez J
    • Abad-Santos F
    • Aldea A
    • et al.
    N/AReaders
    12Citations
    Get full text
  • Bone Mineral Density Referral for Dual-Energy X-Ray Absorptiometry Using Quantitative Ultrasound as a Prescreening Tool in Postmenopausal Women from the General Population: A Cost-Effectiveness Analysis

    • Marín F
    • López-Bastida J
    • Díez-Pérez A
    • et al.
    N/AReaders
    20Citations
    Get full text
  • Safety of olanzapine versus conventional antipsychotics in the treatment of patients with acute schizophrenia. A naturalistic study

    • Alvarez E
    • Bobes J
    • Gómez J
    • et al.
    N/AReaders
    29Citations
    Get full text
  • Economic evaluation in a randomized phase III clinical trial comparing gemcitabine/cisplatin and etoposide/cisplatin in non-small cell lung cancer

    • Sacristán J
    • Kennedy-Martin T
    • Rosell R
    • et al.
    N/AReaders
    33Citations
    Get full text

Editorships

Educación Médica

Editorial Board

2015 - Present

Pharmacoeconomics (Spanish Ed.)

Editorial Board

2012 - Present

The Annals of Internal Medicine

Reviewer

2013 - 2017(4 years)

Professional experience

Senior Medical Director

Eli Lilly and Company